Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Single-center, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety and Tolerability of GB104, and Explore Gut Microbial Composition in Patients Who Completed Curative Colectomy and Planned Therapy of Colorectal Cancer

NCT05943041 is registered in ClinicalTrials.gov with GILongevity as lead sponsor.

NCT NCT05943041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05943041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Single-center, Dose-escalation Phase 1 Clinical Study to Evaluate the Safety and Tolerability of GB104, and Explore Gut Microbial Composition in Patients Who Completed Curative Colectomy and Planned Therapy of Colorectal Cancer
Lead sponsor
GILongevity
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2023
Completion date
December 22, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, colorectal cancer, rectal cancer, rectosigmoid junction cancer, sigmoid colon cancer, solid tumor